INTRODUCTION
============

Dilated cardiomyopathy (DCM) is the most common type of non-ischemic cardiomyopathy, and is characterized by dilation and contractile dysfunction of the left and right ventricles, which is associated with functional alterations leading to heart failure (HF). Various acquired factors affecting cardiomyocyte function and genetic mutations leading to impaired force generation or transmission can both lead to DCM. The pathological remodeling process underlying ventricular dilation involves cardiomyocytes, which undergo eccentric hypertrophy, and also interstitial cells, including resident fibroblasts and macrophages (which are critically involved in tissue fibrosis). Fibrosis contributes adversely to cardiac tissue structure and function, ultimately causing HF ([@b19-0050481]). Connective tissue growth factor (CTGF), a downstream mediator of the TGFβ pathway, plays a key role in this adverse remodeling through the promotion of fibroblast proliferation and extracellular matrix production in connective tissues ([@b1-0050481]; [@b4-0050481]).

Despite recent advances in the pharmacological treatment of individuals with DCM, mortality remains high ([@b42-0050481]). Animal models of DCM are thus required both for testing therapeutic approaches in vivo and for investigating the underlying mechanisms. We recently developed a mouse DCM model, involving cardiac-specific and tamoxifen-inducible disruption of the serum response factor (*SRF*) gene by the Cre-*loxP* method ([@b26-0050481]). SRF is a MADS-box transcription factor essential for cardiac differentiation and maturation ([@b3-0050481]; [@b43-0050481]; [@b21-0050481]; [@b25-0050481]; [@b23-0050481]). SRF binds to CarG-box DNA regulatory elements, thereby regulating several genes involved in cell growth, migration, differentiation, cytoskeleton organization and energy metabolism. Triggering SRF loss in mice results in: the downregulation of proteins involved in force generation and transmission; fibrotic development; and changes in the cytoarchitecture of cardiomyocytes without hypertrophic compensation. This leads to the development of DCM and all mice die from HF around 10 weeks after triggering SRF loss ([@b26-0050481]). This model thus mimics some situations observed in humans ([@b9-0050481]; [@b6-0050481]): several studies suggest that late alterations of SRF function in individuals with cardiomyopathies contribute to propelling the heart towards failure.

Insulin-like growth factor (IGF1) exerts multiple beneficial effects on the heart and can improve myocardial function in pathological situations ([@b12-0050481]; [@b8-0050481]; [@b11-0050481]; [@b33-0050481]). In particular, we described a strong protective effect in induced infarct by a cardiac-specific transgene encoding the muscle-produced IGF1 propeptide (mIGF1), which remains local to the myocardium ([@b30-0050481]). The cardiac signaling cascade induced by mIGF1 preferentially uses the PDK1-SGK1 pathway to increase protein synthesis and growth ([@b30-0050481]). We therefore investigated: (1) whether such local cardiac expression of mIGF1 counteracts some of the deleterious events linked to SRF loss, and (2) the mechanisms by which mIGF1 exerts its beneficial effects. Inducible and cardiac-specific *SRF* knockout mice were crossed with transgenic mice overexpressing mIGF1 in cardiomyocytes and compared with the original DCM model following deletion of the *SRF* gene. Local mIGF1 expression significantly lengthened the lifespan of *SRF* mutant mice, delayed the process leading to DCM and improved cardiac functions. These protective effects were associated with an improvement in cardiomyocyte architecture and the gene expression program, and with a massive reduction of myocardial fibrosis and concomitant amelioration of inflammation. Supplementation with mIGF1 blunted the rise in CTGF expression in cardiomyocytes that results from SRF loss, blocking fibroblast proliferation and related myocardial fibrosis. These findings reveal a key role of SRF in the modulation of cardiac fibrosis, and underscore the importance of tightly regulated SRF expression in the normal heart. They imply a mechanism whereby the mIGF1 propeptide counterbalances the effects of SRF downregulation in human DCM.

RESULTS
=======

Cardiac-specific mIGF1 overexpression improves lifespan of SRF mutants and delays DCM development
-------------------------------------------------------------------------------------------------

Four experimental groups of mice were generated and analyzed after tamoxifen injection: controls, mIGF1 overexpressing, *SRF* mutants and mIGF1 overexpressing/*SRF* mutants (referred to as mIGF1/*SRF* mutants). We initially analyzed two groups of control mice, MHC-MerCreMer and *Sf/Sf*, and observed no phenotypic differences between the two (supplementary material [Fig. S1](http://dmm.biologists.org/lookup/suppl/doi:10.1242/dmm.009456/-/DC1)). Thus, we only kept the *Sf/Sf* group of controls, which has been systematically included in all following experiments. All *SRF* mutant mice (*n*=12) rapidly developed DCM and died 72±1 days (minimum 52 days, maximum 92 days) after tamoxifen injection, consistent with our previous report ([@b26-0050481]). By contrast, mIGF1/*SRF* mutant mice (*n*=13) died 165±3 days (minimum 101 days, maximum 220 days) after tamoxifen injection. Thus, overexpression of mIGF1 in the heart clearly improved life expectancy of *SRF* mutant mice ([Fig. 1A](#f1-0050481){ref-type="fig"}). Whereas *SRF* mutants exhibited enlargement of cardiac chambers and thinning of ventricular walls 2 months after triggering SRF loss, dilation was more moderate in the mIGF1/*SRF* mutants ([Fig. 1B](#f1-0050481){ref-type="fig"}). The milder phenotype in the presence of local IGF1 expression was also reflected in heart weight to body weight ratios \[4.65±0.17 (*n*=9) in control mice, 5.27±0.18 (*n*=8) in mIGF1 mice, 5.75±0.11 (*n*=13) in mIGF1/*SRF* mutants and 7.10±0.76 (*n*=6) in *SRF* mutants\]. Kidney and liver weights to body weight ratios were similar in all groups (data not shown).

![**Effects of cardiac-specific mIGF1 overexpression on survival of *SRF* mutant mice and on cardiac dilation.** (A) Kaplan-Meier curves for *SRF* mutant and mIGF1/*SRF* mutant mice; *P*\<0.0001 with log-rank test. (B) H&E staining of paraffin-embedded heart sections. The dilation of the left (lv) and right (rv) ventricles is less marked in mIGF1/*SRF* than in *SRF* mutant samples. Scale bar: 1 mm.](DMM009456F1){#f1-0050481}

mIGF1 overexpression in cardiomyocytes promotes rescue of heart function
------------------------------------------------------------------------

We assessed cardiac function in the four groups of mice by serial echocardiography immediately before (0 day) and at two different times after (30 and 60 days) tamoxifen injection. At time 0, echocardiographic values were similar for control and cardiac *SRF* pre-mutant groups, and for cardiac mIGF1-overexpressing and cardiac mIGF1/*SRF* pre-mutant groups. However, this last group showed concentric left ventricular (LV) hypertrophy ([Table 1](#t1-0050481){ref-type="table"}). Thus, only data for controls and cardiac mIGF1-overexpressing mice are presented for time 0. At 30 days after tamoxifen treatment, the shortening velocity of circumferential fibers (Vcfc) was slightly lower in the *SRF* mutant group, and the mIGF1/*SRF* mutant group showed an intermediate phenotype with a less acute LV hypertrophy and no significant LV functional alteration ([Table 1](#t1-0050481){ref-type="table"}). On day 60, mIGF1/*SRF* mutants showed a significant improvement of cardiac function when compared with *SRF* mutant mice: LV contractility parameters such as Vcfc, ejection fraction (EF), and systolic velocity at mitral annulus (Sa) and posterior wall (Spw) were similar to those obtained for control and mIGF1-overexpressing mice. By contrast, a strong decrease of these four parameters was observed in *SRF* mutant mice ([Table 1](#t1-0050481){ref-type="table"}). Moderate left atrial (LA) remodeling was observed in both *SRF* mutant and mIGF1/*SRF* mutant mice, with slight LV enlargement (LV end-diastolic diameter increase; LVEDD) in the *SRF* mutant group. This suggests the occurrence of HF in this latter group, associated with an elevated LV filling pressure as indicated by the ratio of transmitral blood velocity to mitral annulus diastolic velocity (E/Ea; [Table 1](#t1-0050481){ref-type="table"}).

###### 

Echocardiographic measurements of control, mIGF1, *SRF* mutant and mIGF1/*SRF* mutant mice 0, 30 and 60 days after tamoxifen treatment

![](DMM009456T1)

Cardiac cytoarchitecture is normalized in mIGF1/*SRF* mutant mice
-----------------------------------------------------------------

Hearts of the four different genotypes were examined morphologically and histologically. Whereas hematoxylin and eosin (H&E) staining of cardiac transverse sections revealed enlarged interstitial spaces between cardiomyocytes in *SRF* mutant mice, these spaces were substantially smaller in mIGF1/*SRF* mutant mice ([Fig. 2A](#f2-0050481){ref-type="fig"}). Cardiac cytoarchitecture was examined by confocal microscopic analysis after immunostaining for vinculin, a cytoskeletal protein, and staining for polymerized F-actin with phalloidin-TRITC. Although mIGF1/*SRF* mutant cardiomyocytes were still heterogeneous in size and were sometimes stretched, as in *SRF* mutants, their shape and alignment were more regular, without gaps between cells ([Fig. 2B](#f2-0050481){ref-type="fig"}). In addition, intercalated discs in *SRF* mutant hearts were dysmorphic, whereas most intercalated discs in mIGF1/*SRF* mutants displayed a more normal morphology ([Fig. 2B](#f2-0050481){ref-type="fig"}; supplementary material [Fig. S2](http://dmm.biologists.org/lookup/suppl/doi:10.1242/dmm.009456/-/DC1)). Phalloidin staining revealed a better preservation of sarcomere organization in mIGF1/*SRF* than *SRF* mutant hearts ([Fig. 2B](#f2-0050481){ref-type="fig"}). Cardiomyocytes from mIGF1-overexpressing mice were particularly square and thick with a regular alignment ([Fig. 2B](#f2-0050481){ref-type="fig"}).

Morphometric analysis revealed that, whereas *SRF* mutant cardiomyocytes had increased length and decreased width compared with controls, mIGF1/*SRF* mutant cardiomyocyte size distribution was closer to that of controls ([Fig. 2C](#f2-0050481){ref-type="fig"}). Noticeably, mIGF1-overexpressing cardiomyocytes were particularly short and wide ([Fig. 2C](#f2-0050481){ref-type="fig"}). Thus, the eccentric stretching of cardiomyocytes that is characteristic of DCM is considerably attenuated when mIGF1 is overexpressed. Ultrastructural analysis of mIGF1/*SRF* mutants by electron microscopy confirmed that mIGF1 overexpression normalized sarcomeric organization and substructure, and the abundance and alignment of mitochondria (supplementary material [Fig. S3](http://dmm.biologists.org/lookup/suppl/doi:10.1242/dmm.009456/-/DC1)).

mIGF1 improves the cardiac gene expression program in *SRF* mutant mice
-----------------------------------------------------------------------

The absence of SRF results in profound alterations of the cardiac gene expression program, with the downregulation of main SRF target genes and late activation of the stress-induced gene *ANF* ([@b26-0050481]). We analyzed the effects of mIGF1 overexpression, in the context of SRF loss, on the cardiac gene expression program both by real-time reverse-transcriptase PCR (RT-PCR) and northern blot analysis ([Fig. 3](#f3-0050481){ref-type="fig"}). After induction by tamoxifen, SRF was lost from most cardiomyocytes, but a small percentage of the cardiomyocyte population continued producing SRF (∼20%; supplementary material [Fig. S1](http://dmm.biologists.org/lookup/suppl/doi:10.1242/dmm.009456/-/DC1)). Because of this mosaic inactivation of *SRF*, the results ([Fig. 3](#f3-0050481){ref-type="fig"}) only reflect global changes in gene expression, and might be different within the subpopulations of cardiac cells. Triggering SRF loss led to a similar decrease in cardiac α-actin mRNA levels irrespective of local mIGF1 expression; the abundance of skeletal α-actin mRNAs increased in *SRF* mutant hearts but increased significantly less in mIGF1/*SRF* mutant hearts ([Fig. 3A,B](#f3-0050481){ref-type="fig"}). Skeletal α-actin immunostaining on paraffin-embedded heart sections confirmed these findings (supplementary material [Fig. S4](http://dmm.biologists.org/lookup/suppl/doi:10.1242/dmm.009456/-/DC1)). Local mIGF1 expression led also to an attenuation of the switch in myosin heavy chain (MHC) isoform expression associated with SRF loss, with a significant increase in the level of postnatal *α-MHC* mRNA and a trend towards a decrease in the amount of embryonic β-MHC mRNAs ([Fig. 3A](#f3-0050481){ref-type="fig"}). Expression of *MCK*, an SRF target gene involved in energy flux, remained lower in mIGF1/*SRF* than in *SRF* mutant mice ([Fig. 3A](#f3-0050481){ref-type="fig"}). Expression of the *SERCA2* and *NCX1* genes, encoding proteins involved in Ca^2+^ reuptake and extrusion, respectively, which was weak in *SRF* mutant hearts, was partly restored in the presence of mIGF1 ([Fig. 3](#f3-0050481){ref-type="fig"}). Importantly, expression of the stress-induced gene *ANF* was normalized in mIGF1/*SRF* mutant hearts, compared with elevated levels observed in the *SRF* mutant ([Fig. 3](#f3-0050481){ref-type="fig"}). Elevated *BNP* expression in *SRF* mutant hearts was also normalized in the mIGF1/*SRF* mutant ([Fig. 3A](#f3-0050481){ref-type="fig"}). Thus, the globally compromised cardiac gene expression pattern associated with SRF loss is improved by locally acting mIGF1.

![**Improvement of the cardiomyocyte architecture in mIGF1/*SRF* mutant mice.** (A) H&E staining of paraffin-embedded heart sections illustrating the amelioration of intercellular gaps in *SFR* mutants in the presence of mIGF1. Scale bars: 20 μm. (B) Confocal microscopy of cardiac sections labeled with Alexa-Fluor-568--phalloidin (red) for polymerized actin, anti-vinculin FITC (green) and DAPI (blue). Note the better cardiac cytoarchitecture in mIGF1/*SRF* mutant than *SRF* mutant mice: intercalated discs are substantially enlarged and irregularly shaped in *SRF* mutants, but mostly display almost normal morphology in mIGF1/*SRF* mutants (arrows). Disc sizes: min. 1 μm -- max. 1.5 μm for controls and mIGF1; min. 1.5 μm -- max. 3.5 μm for mIGF1/*SRF* mutants; and min. 4 μm -- max. 6.7 μm for *SRF* mutants. Scale bars: 30 μm. (C) Distribution of cardiomyocyte lengths and widths in the four groups of mice; *n*=200 for each group (four different mice per group).](DMM009456F2){#f2-0050481}

![**Analysis of gene expression in the hearts of mIGF1/*SRF* mutant and *SRF* mutant mice.** (A) qRT-PCR analysis of control (*n*=7), mIGF1 (*n*=6), *SRF* mutant (*n*=6) and mIGF1/*SRF* mutant (*n*=10) mouse mRNA, using cyclophilin as internal control. Data are presented as means ± s.e.m. \*, \*\* and \*\*\* indicate significant difference at *P*\<0.05, *P*\<0.01 and *P*\<0.001, respectively, versus the control group, and ^§^, ^§§^ and ^§§§^ indicate significant difference at *P*\<0.05, *P*\<0.01 and *P*\<0.001, respectively, between the mIGF1/*SRF* mutant and the *SRF* mutant groups. (B) Northern blot analysis of gene expression in the four groups of mice. We used 18S rRNA as a loading control.](DMM009456F3){#f3-0050481}

mIGF1 counters SRF-loss-related myocardial fibrosis and CTGF expression
-----------------------------------------------------------------------

Masson's trichrome staining consistently revealed interstitial fibrosis in *SRF* mutant hearts, but no such fibrosis was detected in the presence of mIGF1 ([Fig. 4A](#f4-0050481){ref-type="fig"}). Connexin 45 is a gap junction protein primarily associated with cardiac fibroblasts ([@b18-0050481]). Connexin 45 and phalloidin co-immunostaining revealed overgrowing cardiac fibroblasts within the large spaces in the *SRF* mutant myocardium, but not in mIGF1/*SRF* mutant, control or mIGF1 hearts ([Fig. 4B](#f4-0050481){ref-type="fig"}). These results were confirmed by immunostaining for vimentin, another marker of cardiac fibroblasts (supplementary material [Fig. S5](http://dmm.biologists.org/lookup/suppl/doi:10.1242/dmm.009456/-/DC1)) ([@b5-0050481]).

To assess whether cardiac fibroblast proliferation was involved in cardiac fibrosis, we quantified the Ki67 protein, present only in nuclei of cycling cells ([@b15-0050481]; [@b32-0050481]), in the various mouse genotypes. Co-immunostaining for vinculin and Ki67 indicated that the cardiomyocytes were not replicating, but that many more interstitial cells were dividing in *SRF* mutant mice than in the other groups of mice ([Fig. 4C](#f4-0050481){ref-type="fig"}): there were four times more Ki67-positive cells per heart section in *SRF* mutants than in the mIGF1/*SRF* and mIGF1 mutants and controls, which all displayed similar low numbers of dividing interstitial cells ([Fig. 4D](#f4-0050481){ref-type="fig"}). Co-immunostaining for Ki67 and connexin 45 confirmed that the larger numbers of Ki67-positive cells in *SRF* mutant hearts was associated with the proliferation of cardiac fibroblasts ([Fig. 4E](#f4-0050481){ref-type="fig"}).

To investigate the impact of mIGF1 on the development of fibrosis, we quantified the expression of several genes involved in this process by RT-PCR. Increased collagen production in *SRF* mutant hearts was normalized in mIGF1/*SRF* mutant hearts, as assessed by procollagen type 1α1 but not type 3α1 transcripts ([Fig. 5A](#f5-0050481){ref-type="fig"}). Two cardioprotective genes, adiponectin and *UCP1*, were induced in mIGF1/*SRF* mutant but not *SRF* mutant hearts ([Fig. 5A](#f5-0050481){ref-type="fig"}). Cardiac *CTGF* expression has been documented both in cardiomyocytes and in fibroblasts. *CTGF* mRNA and protein levels were much higher in *SRF* mutant hearts than in control and mIGF1 hearts, and these high levels were not observed in mIGF1/*SRF* mutants ([Fig. 5A,B](#f5-0050481){ref-type="fig"}). A similar, but not significant, trend was observed for *TGFβ* mRNA levels ([Fig. 5A](#f5-0050481){ref-type="fig"}). Immunohistochemical detection of CTGF protein in heart sections was used to determine the cell specificity of these expression patterns. In control and mIGF1 hearts, CTGF immunoreactivity was extremely weak and exclusively localized outside cardiomyocytes ([Fig. 6](#f6-0050481){ref-type="fig"}). By contrast, in *SRF* mutant hearts, CTGF was abundant not only in interstitial spaces corresponding to proliferating fibroblasts but also in a large number of small *SRF*-null cardiomyocytes. Noticeably, the few SRF-positive hypertrophic cardiomyocytes were all negative for CTGF ([Fig. 6](#f6-0050481){ref-type="fig"}). In the presence of mIGF1, *SRF* mutant hearts displayed a completely normalized CTGF expression pattern, similar to that seen in controls. Taken together, these findings suggest that: (1) the increased CTGF expression observed in *SRF* mutant hearts stems from both a direct effect of SRF loss on *CTGF* gene expression within cardiomyocytes and from fibroblast proliferation, and (2) cardiac-specific mIGF1 expression counteracts the rise in CTGF production both in *SRF* mutant cardiomyocytes and in cardiac fibroblasts independently of SRF loss, thus attenuating cardiac fibroblast proliferation.

![**Effects of cardiac-specific mIGF1 overexpression on fibrosis and cell proliferation.** (A) Histological analysis by Masson's trichrome staining shows intensive fibrosis only in *SRF* mutant mouse myocardium. Scale bars: 10 μm. (B) Visualization of cardiac fibroblasts by connexin 45 staining of heart sections from control, mIGF1, *SRF* mutant and mIGF1/*SRF* mutant mice. Longitudinal frozen section showing the localization of cardiac fibroblasts stained with connexin 45 (red) and polymerized actin in myocytes labeled with Alexa-Fluor-488--phalloidin (green). Scale bars: 40 μm. These results are representative of two independent experiments. (C) Confocal microscopic view of Ki67 labeling (pink; at arrows). Labeling is stronger in the *SRF* mutant than the mIGF1/*SRF* mutant, and is exclusively located in the extracellular matrix. Longitudinal (L) and transversal (T) sections show the same tissue, with cardiomyocytes being identified by labeling with anti-vinculin FITC (green) and nuclei with DAPI (blue). Scale bars: 30 μm. (D) Quantification of Ki67 labeling per heart section reveals four times more labeling in *SRF* mutant hearts than all other groups. Data are presented as means ± s.e.m. \*\*\*, significant difference versus the control group, at *P*\<0.001; ^§§§^, significant difference between the mIGF1/*SRF* mutant and the *SRF* mutant groups, at *P*\<0.001. These results are representative of three independent experiments. (E) Confocal microscopic view of Ki67 labeling (green; at arrows), connexin 45 staining (red) and DAPI labeling of nuclei (blue), showing that Ki67 labeling coincides with cardiac fibroblasts. Scale bars: 30 μm.](DMM009456F4){#f4-0050481}

mIGF1 overexpression modulates the inflammatory response in *SRF* mutant mice
-----------------------------------------------------------------------------

There is growing evidence that fibrosis and inflammation are mechanistically linked in the heart. We therefore investigated the expression of cytokines and chemokines that promote inflammation in the different mouse genotypes. Although a strong increase in proinflammatory *IL-6* transcripts was observed in *SRF* mutant hearts, only a limited increase was observed in mIGF1/*SRF* mutants ([Fig. 7A](#f7-0050481){ref-type="fig"}). The inverse profile was observed for the transcripts of the anti-inflammatory cytokine IL-4 ([Fig. 7A](#f7-0050481){ref-type="fig"}). Transcripts encoding IL-1β, another inflammatory cytokine, and IL-10, an anti-inflammatory cytokine, were not significantly affected by mIGF1 overexpression ([Fig. 7A](#f7-0050481){ref-type="fig"}). Expression of the monocyte chemoattractant protein 1 (*MCP1*) and cyclooxygenase 2 (*COX2*; encoding a prostaglandin-endoperoxide synthase involved in the inflammatory response) genes was significantly activated in *SRF* mutant mice, and this activation was attenuated in mIGF1/*SRF* mutants ([Fig. 7A](#f7-0050481){ref-type="fig"}). Immunostaining with F4/80 antibody revealed macrophages in heart sections from all mouse groups; however, the signal intensity was much stronger in *SRF* mutant sections than in control and mIGF1/*SRF* mutant sections ([Fig. 7B](#f7-0050481){ref-type="fig"}). In summary, these analyses show that local mIGF1 attenuates the inflammatory response induced by SRF loss and the concomitant cardiac remodeling.

![**Modulation of the expression of genes involved in cardiac fibrosis by local mIGF1 overexpression.** (A) qRT-PCR analysis of mRNA of genes that are markers of cardiac tissues in control (*n*=7), mIGF1 (*n*=6), *SRF* mutant (*n*=6) and mIGF1/*SRF* mutant (*n*=10) mice. Cyclophilin was used as control. Data are presented as means ± s.e.m. \*, \*\* and \*\*\*, significant difference versus the control group, at *P*\<0.05, *P*\<0.01 and *P*\<0.001, respectively; ^§^, ^§§^ and ^§§§^, significant difference between the mIGF1/*SRF* mutant and the *SRF* mutant groups, at *P*\<0.05, *P*\<0.01 and *P*\<0.001, respectively. (B) Western blot analysis of CTGF protein.](DMM009456F5){#f5-0050481}

![**Effects of local mIGF1 overexpression on CTGF expression.** Immunofluorescence labeling of SRF (red), CTGF (orange) and vinculin (green) on serial heart sections of control, *SRF* mutant and mIGF1/*SRF* mutant mice. The orange arrows indicate CTGF-positive/*SRF*-null cardiomyocytes and the white arrows indicate SRF-positive/CTGF-negative cardiomyocytes. The orange arrowheads show CTGF outside of cardiomyocytes in *SRF* mutant mice. These data were verified by analyzing more than 50 fields per heart section in three independent experiments. The results presented are representative of three independent experiments. Scale bar: 30 μm.](DMM009456F6){#f6-0050481}

DISCUSSION
==========

IGF1 is a peptide that acts both as a systemic growth factor and locally in an autocrine/paracrine manner, and has a key role in cardiac function and in cardiac growth ([@b28-0050481]). The locally acting mIGF1 propeptide is clearly beneficial both in enhancing repair of the heart following injury and in protecting cardiomyocytes from hypertrophic and oxidative stresses ([@b30-0050481]). Here, we report an analysis of the effects of cardiac-specific mIGF1 expression in a mouse model of DCM based on *SRF* gene disruption. Our in vivo findings demonstrate a crucial role of SRF in controlling *CTGF* expression within cardiomyocytes and thus in regulating the fibrogenic process. Cardiac supplementation with mIGF1 diminishes DCM progression, which is associated with SRF loss, at least in part by counteracting both the inflammatory response and fibrosis, mechanistically linked processes directly contributing to adverse myocardial remodeling and HF. The beneficial effects of mIGF1 in the DCM model included the blockade of induction of both CTGF and proinflammatory cytokines, and the inhibition of cardiac fibroblast proliferation.

![**Effects of cardiac-specific mIGF1 overexpression on the inflammation profile.** (A) qRT-PCR assays of *IL-1β*, *IL-4*, *IL-6*, *IL-10*, *MCP1* and *COX2* mRNA in cardiac tissue from control (*n*=7), mIGF1 (*n*=6), *SRF* mutant (*n*=6) and mIGF1/*SRF* mutant (*n*=10) mice. Cyclophilin mRNA was used as a control. Values are means ± s.e.m. \*, \*\* and \*\*\*, significant difference versus the control group at *P*\<0.05, *P*\<0.01 and *P*\<0.001, respectively; ^§^ and ^§§^, significant difference between the mIGF1/*SRF* mutant and the *SRF* mutant group at *P*\<0.05 and *P*\<0.01, respectively. (B) Immunofluorescence labeling with F4/80 (red), vinculin (green) and DAPI (blue) on serial heart sections of control, *SRF* mutant and mIGF1/*SRF* mutant mice. The arrows indicate inflammatory cells. These results are representative of three independent experiments. Scale bars: 30 μm.](DMM009456F7){#f7-0050481}

We previously reported that triggering *SRF* gene disruption in adult cardiomyocytes led to DCM characterized by LV dilation, a progressive loss in contractility and fatal HF ([@b26-0050481]). The introduction of a cardiac-restricted *mIGF1* transgene in *SRF* mutant mice attenuated most of these ventricular remodeling phenomena: mIGF1-associated improvements in LVEDD, Sa, Spw, Vcfc and EF activities indicate a functional preservation of the heart with a delay in cardiac dilation and the doubling of overall survival times.

Previous reports have shown that administration of the systemic IGF1 isoform improves cardiac function in humans and in animal models of DCM and HF ([@b12-0050481]; [@b8-0050481]; [@b10-0050481]; [@b11-0050481]; [@b33-0050481]). Transgenic IGF1 overexpression also led to morphological and functional cardiac improvements in a tropomodulin-overexpressing transgenic mouse model ([@b40-0050481]). However, in this model, the IGF1-mediated correction of abnormalities was mainly attributed to myocyte regeneration due to the increased number of myocytes associated with Ki67 labeling ([@b40-0050481]). Protection in post-infarct experiments has also been suggested to be a consequence of increased cardiomyocyte proliferation induced by the *mIGF1* transgene ([@b30-0050481]). By contrast, our findings do not support mIGF1 exerting its beneficial effects on DCM through the recruitment of cardiomyocyte precursor cells. Indeed, tamoxifen-induced *SRF* disruption is cardiomyocyte-specific and time-restricted, so any subsequent recruitment of precursor cells would have resulted in a new population of SRF-positive cardiomyocytes. At 2 months after tamoxifen injection, the abundance of the SRF protein in mIGF1/*SRF* mutant hearts remained low and the number of cardiomyocytes escaping *SRF* disruption had not increased. Accordingly, expression of downstream cardiac α-actin and *MCK* genes was also not elevated.

In another model, that of mosaic inactivation of SRF in the myocardium using Desmin-Cre transgenic mice, which express the Cre recombinase in only 50% of the cardiomyocytes, we could show that cardiomyocytes lacking SRF became thin and elongated, whereas cardiomyocytes still expressing SRF became hypertrophic ([@b17-0050481]). Skeletal α-actin expression, a marker of cardiac hypertrophy, was activated in SRF-positive cardiomyocytes only ([@b17-0050481]). Accordingly, in our model, the small percentage of the cardiomyocyte population still expressing SRF (∼20%) is expected to activate a typical concentric hypertrophic gene program to compensate for the ∼80% of cardiomyocytes depleted of SRF, which undergo eccentric elongation. Similarly, these cardiomyocytes continuing to express SRF most probably account for the reactivation of the fetal gene program, a molecular hallmark of progression towards HF, and for the increased expression of skeletal α-actin and β-MHC isoforms observed in *SRF* mutant hearts. Interestingly, the activation of this fetal gene program in *SRF* mutant hearts was partly counteracted by mIGF1. This result is consistent with the blockade of the fetal gene program by mIGF1 propeptide observed in cultured cardiomyocytes ([@b38-0050481]): in these experiments, fully processed IGF1 was ineffective, suggesting that IGF1 propeptides could have different protective effects. In our model, expression of *SERCA2*, *NCX1* and *α-MHC* was restored to a certain extent in mIGF1/*SRF* mutants and contributed to the improved contraction rates. mIGF1 expression might therefore exert beneficial effects by limiting stress, and maintaining Ca^2+^ dynamics and cardiac performance. Restoration of Ca^2+^ dynamics by IGF1 has also been described in the tropomodulin-overexpressing transgenic mouse model ([@b40-0050481]).

The presence of the mIGF1 propeptide had several major beneficial effects at the cellular level: it was associated with relatively rectangular cardiac cell shapes, and preserved the continuity of interactions and communications between cardiomyocytes. mIGF1 also attenuated alterations in intercalated discs, which play a crucial role in force transmission and their disorganization leads to the development of DCM ([@b14-0050481]; [@b16-0050481]). Cardiac α-actin is the major actin isoform in cardiomyocytes and constitutes the main component of the thin filament of the sarcomere ([@b37-0050481]). Despite an abundance of cardiac α-actin transcripts in mIGF1/*SRF* mutant cardiomyocytes that was lower than in controls, wild-type levels of polymerized actin were maintained. Our results suggest that mIGF1 positively affects actin dynamics, either through increased translation or increased stability.

Most importantly, both the induction of the inflammatory response and cardiac fibrotic development in *SRF* mutant hearts were substantially attenuated in the presence of mIGF1. Indeed, mIGF1 counteracted increases, induced by loss of SRF, in the amounts of mRNA for *MCP1*, *IL-6* and *COX-2*, and decreases in that for *IL-*4 and collagen production. Numerous studies underscore the important role played by TGFβ and one of its downstream mediators, CTGF, in the development of fibrosis ([@b1-0050481]; [@b4-0050481]). Elevated CTGF protein levels were observed in cardiac tissue from patients with HF and correlated with the degree of myocardial fibrosis ([@b20-0050481]). Consistent with these observations, levels of the transcripts of these two factors were closely correlated and higher in *SRF* mutant than control hearts; their abundance was completely normalized by the presence of mIGF1. CTGF regulates fibrosis by inducing fibroblast proliferation and extracellular matrix production, and its high concentration therefore probably explains the fibroblast proliferation and fibrosis in *SRF* mutants. Several studies also implicate CTGF in the regulation of the inflammatory process by inducing MCP1 and IL-6 in cardiomyocytes and by acting as a chemotactic factor for monocytes ([@b29-0050481]; [@b39-0050481]). Thus, normalization of CTGF levels by mIGF1 contributes to decreases in both inflammation and fibrosis.

Increased CTGF expression in *SRF* mutants was observed both in cardiac fibroblasts and *SRF*-null cardiomyocytes, but never in SRF-positive cardiomyocytes. This strongly implicates SRF in repressing CTGF expression in cardiomyocytes, directly or through a repressor. Indeed, analysis of the mammalian 'CArGome' (CArG elements in the genome) identified CTGF as a potential SRF target, and the presence of a 'CArG' box in the *CTGF* promoter has been established ([@b36-0050481]; [@b22-0050481]). In the same way, SRF has been shown to control *CTGF* transcription in human umbilical vein endothelial cells ([@b22-0050481]) and to operate as a CTGF repressor in neurons ([@b35-0050481]). Interestingly, the *CTGF* transcript is a target of miR133, the transcription of which is controlled by SRF ([@b7-0050481]; [@b24-0050481]; [@b13-0050481]). Such a mechanism might also account for the SRF-mediated repression of *CTGF* expression. The abundance of CTGF-positive/SRF-null cardiomyocytes in SRF mutant hearts correlated with the degree of the interstitial fibrosis and increased procollagen type 1α1 and 3α1 expression, suggesting that CTGF produced and secreted by *SRF*-null cardiomyocytes can exert a paracrine control on cardiac fibroblast functions. Also, paracrine regulation of oligodendrocyte differentiation by SRF-directed CTGF repression in neurons was recently demonstrated ([@b35-0050481]). In the human context, alterations of SRF function due to SRF cleavage by caspase 3 and/or aberrant splicing of *SRF* transcripts have been described in cardiomyocytes from severely failing hearts, accounting for altered expression of various cardiac-specific proteins that are associated with HF ([@b9-0050481]; [@b6-0050481]; [@b41-0050481]). Such impaired SRF activity might also play a crucial role in promoting fibrosis and adverse cardiac remodeling, thus propelling the heart towards failure.

How does mIGF1 counteract loss of SRF function? The dramatic rescue by the *mIGF1* transgene in the DCM model could be the consequence of numerous effects: limiting cellular stress and inflammation by increasing the expression of antioxidant *UCP1* and adiponectin, normalization of *CTGF* expression, and decreasing procollagen gene expression and subsequent fibrosis. Our results are consistent with the reduced fibrogenesis observed following IGF1 induction in activated hepatic stellate cells after liver injury and the accelerated skeletal muscle regeneration by *mIGF1* transgene expression, which rapidly modulates inflammatory cytokines and chemokines ([@b31-0050481]; [@b27-0050481]). The normalization of *CTGF* mRNA levels is in favor of IGF1 having a strong antagonistic effect on *CTGF* transcription. Indeed, IGF1 inhibits CTGF expression through the PI3K-Akt signaling pathway ([@b44-0050481]). In accordance with our results in the heart, *IGF1* gene transfer to cirrhotic liver induces fibrolysis and reduces fibrogenesis via the downregulation of profibrogenic molecules, including TGFβ and CTGF ([@b31-0050481]).

In summary, our studies in vivo show that the elevated CTGF expression observed in *SRF* mutant hearts stems from both fibroblast proliferation and direct effects of SRF loss on *CTGF* gene expression within cardiomyocytes. Supplemental mIGF1 counteracts the effects of CTGF induction at both levels, blocking cardiac fibroblast proliferation, thereby counteracting both the inflammatory response and fibrosis, protecting the heart against adverse remodeling and attenuating the progression of DCM. These results advance our understanding of the mechanistic basis of HF. They also suggest that mIGF1 propeptide remaining local to the myocardium is a promising therapeutic option for HF.

METHODS
=======

Transgenic mice
---------------

The generation and characterization of transgenic mice with inducible cardiac-specific SRF loss (α-MHC-MerCreMer: *Sf/Sf*) and those overexpressing mIGF1 in cardiomyocytes (α-MHC-mIGF1; abbreviated to mIGF1) have been described previously ([@b26-0050481]; [@b30-0050481]). The mIGF1 strain was backcrossed at least five times onto a C57BL/6N genetic background and was then crossed with mice homozygous for floxed *SRF* alleles (abbreviated to *Sf/Sf*) to generate α-MHC-mIGF1: *Sf/Sf* mice. Theα-MHC-mIGF1: *Sf/Sf* mice were crossed with α-MHC-MerCreMer: *Sf/Sf* mice to generate the four experimental groups of mice that were systematically included in all experiments: controls (*Sf/Sf*), cardiac mIGF1-overexpressing mutants (α-MHC-mIGF1: *Sf/Sf*), cardiac *SRF* pre-mutants (α-MHC-MerCreMer: *Sf/Sf*) and cardiac mIGF1-overexpressing/*SRF* pre-mutants (α-MHC-mIGF1: α-MHC-MerCreMer: *Sf/Sf*). Mice were selected on the basis of the results of PCR analysis of tail DNA. For all experiments, four groups of 2-month-old mice (including at least six male and six female mice per group) were given intraperitoneal tamoxifen citrate salt diluted in ethanol (20 μg/g per day; Sigma) injections daily for 4 consecutive days. All analyses were performed 2 months after the first tamoxifen injection ([@b26-0050481]). In our experimental conditions, no negative impact of Cre and/or tamoxifen injections was observed in our two initial groups of controls: α-MHC-MerCreMer and *Sf/Sf* (supplementary material [Fig. S1](http://dmm.biologists.org/lookup/suppl/doi:10.1242/dmm.009456/-/DC1)). Thus, we only kept the *Sf/Sf* group of controls, which was systematically included in all experiments. Cre-mediated excision of floxed *SRF* alleles was verified as previously described. The resulting SRF protein loss (75--80% by comparison with the controls) was equivalent in the *SRF* mutant mice overexpressing or not overexpressing mIGF1 (supplementary material [Fig. S6](http://dmm.biologists.org/lookup/suppl/doi:10.1242/dmm.009456/-/DC1)). Expression of the *mIGF1* gene in the heart after triggering SRF loss was confirmed by PCR with specific primers that recognize the mRNAs for both endogenous and transgenic IGF1 isoforms. In control conditions, the heart produced small but detectable amounts of *IGF1* mRNA; in mIGF1 and mIGF1/*SRF* mutant mice, the amounts of *IGF1* mRNA were 470-times and 230-times higher than controls, respectively (supplementary material [Fig. S7](http://dmm.biologists.org/lookup/suppl/doi:10.1242/dmm.009456/-/DC1)). This study conformed to institutional guidelines for the use of animals in research.

Echocardiography
----------------

Echocardiography was performed as previously described ([@b26-0050481]) with a Toshiba Powervision 6000, SSA 370A device equipped with an 8- to 14-MHz linear transducer; mice were under isoflurane anesthesia (0.75% to 1% oxygen) with spontaneous ventilation. Data were transferred online to a computer for offline analysis.

Histological analysis, immunohistochemistry and morphometric measurements
-------------------------------------------------------------------------

Histological analysis and immunohistochemistry using anti-SRF (1:100; Santa Cruz), anti-CTGF (1:100; Santa Cruz) and anti-skeletal actin (1:20) were performed as previously described ([@b26-0050481]). Fibrosis was detected by Masson's trichrome and hematoxylin-eosin-saffron stainings. Immunofluorescence analysis of frozen sections involved the following primary antibodies: anti-SRF (1:500; Santa Cruz), anti-vinculin (1:500; hVIN-1, Sigma), anti-connexin-45 (1:400; Chemicon), anti-vimentin (1:100; Progen), anti-F4/80 (1:500; Abcam) and anti-Ki67 (1:750; Abcam) followed by incubation with Cy3- or Alexa-Fluor-488-coupled secondary antibody. Alexa-Fluor-488--phalloidin or TRITC-labeled phalloidin (0.33 μmol/l; Sigma) was used to detect polymerized actin.

The maximal length and width of cardiomyocytes were measured by confocal microscopy following vinculin-phalloidin immunofluorescence staining using ImageJ software (version 1.39u). Ten to 15 fields corresponding to more than 150 cardiac cells per group of mice were analyzed. Measurements were performed on samples from at least four individuals in each group.

Electron microscopy
-------------------

Electron microscopy was performed on hearts of control, mIGF1, *SRF* mutant and IGF1/*SRF* mutant mice as previously described ([@b2-0050481]).

Western blot analysis
---------------------

Western blotting was performed as previously described ([@b25-0050481]) using anti-SRF (1:800), anti-CTGF (1:250) and anti-GAPDH (1:2000) antibodies (Santa Cruz) in 5% milk.

Quantitative RT-PCR analysis
----------------------------

Total RNAs were extracted from hearts using the RNeasy fibrous tissue mini kit (Qiagen) and were reversed transcribed with Moloney murine leukemia virus reverse transcriptase (Invitrogen) and random hexamers (Promega) to generate cDNAs. PCR analysis was then performed with SYBR green PCR technology (ABGene). The Primer3 program (<http://frodo.wi.mit.edu/primer3/>) was used to select primers (available on request). Cyclophilin mRNA was used as the reference transcript.

###### TRANSLATIONAL IMPACT

**Clinical issue**

Despite recent advances in the pharmacological treatment of individuals with dilated cardiomyopathy (DCM), mortality remains high. Cardiac fibrosis is crucially involved in the adverse remodeling process occurring in DCM that leads to cardiac dysfunction and failure. Accurate animal models of DCM are important both for understanding the mechanisms involved in the progression to failure and for testing new therapeutic approaches. Here, the authors investigate whether insulin-like growth factor 1 (IGF1) has a beneficial effect in a mouse model of DCM.

**Results**

The authors address this issue in a mouse model of DCM in which temporally controlled cardiac-specific inactivation of the gene encoding serum response factor (*SRF*; which is essential for normal cardiac differentiation and maturation) leads to progressively reduced contractility and mimics some features observed in individuals with cardiomyopathies. Cardiac expression of a locally acting IGF1 propeptide (mIGF1) limits DCM progression in this model, conferring a marked improvement in cardiac function and doubling lifespan. Beneficial effects of mIGF1 include blunting the induction of connective tissue growth factor (CTGF) expression in cardiomyocytes, an effect of SRF deficiency. This results in the blockade of myocardial fibrosis and a concomitant amelioration of inflammation.

**Implications and future directions**

These data uncover a key role for SRF in modulating cardiac fibrosis and repressing cardiac CTGF expression, exerting paracrine control on cardiac fibroblast function. Amelioration of fibrosis and DCM caused by SRF deficiency through expressing mIGF1 propeptide represents a promising therapeutic avenue for treating cardiac failure in humans. Some evidence suggests that SRF dysfunction in individuals with DCM contributes to heart failure. Therefore, further understanding of the underlying mechanisms in this model will help to develop treatments that counteract the adverse cardiac remodeling that is linked to alterations of SRF function in individuals with DCM.

Northern blot analysis
----------------------

Northern blotting was carried out with 5 μg of total RNA as previously described ([@b34-0050481]). The membranes were successively hybridized at 65°C with murine cDNA probes for *SRF*, cardiac and skeletal α-actins, *α-MHC*, *ANF* and *SERCA2* labeled with \[a^32^P\]dCTP using the Megaprime DNA labeling system (Amersham). Hybridization with an 18S ribosomal probe was used for sample normalization.

Statistical analysis
--------------------

Survival and morphometric results are expressed as means ± s.e.m. For the survival data, Kaplan-Meier analyses were performed using the log-rank test. For the morphometric data, the significance of differences between means was assessed with Student's *t*-test. *P*-values of \<0.05 were considered to be statistically significant.
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